Literature DB >> 27999733

Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups.

Christina D Pham1, Duane A Mitchell1.   

Abstract

Medulloblastoma (MB) is the most common pediatric brain tumor with few reports of successful immunologic targeting. We have recently demonstrated the immune tumor microenvironment as well as response to immune checkpoint blockade differ across subtypes of murine MB.

Entities:  

Keywords:  Immunotherapy; medulloblastoma; tumor microenvironment

Year:  2016        PMID： 27999733      PMCID： PMC5139647          DOI： 10.1080/2162402X.2016.1144002

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  Vaccination strategies for neuro-oncology.

Authors:  John H Sampson; Duane A Mitchell
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

2.  Tumor-associated macrophages in SHH subgroup of medulloblastomas.

Authors:  Ashley S Margol; Nathan J Robison; Janahan Gnanachandran; Long T Hung; Rebekah J Kennedy; Marzieh Vali; Girish Dhall; Jonathan L Finlay; Anat Erdreich-Epstein; Mark D Krieger; Rachid Drissi; Maryam Fouladi; Floyd H Gilles; Alexander R Judkins; Richard Sposto; Shahab Asgharzadeh
Journal:  Clin Cancer Res       Date:  2014-10-24       Impact factor: 12.531

3.  An animal model of MYC-driven medulloblastoma.

Authors:  Yanxin Pei; Colin E Moore; Jun Wang; Alok K Tewari; Alexey Eroshkin; Yoon-Jae Cho; Hendrik Witt; Andrey Korshunov; Tracy-Ann Read; Julia L Sun; Earlene M Schmitt; C Ryan Miller; Anne F Buckley; Roger E McLendon; Thomas F Westbrook; Paul A Northcott; Michael D Taylor; Stefan M Pfister; Phillip G Febbo; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

4.  Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.

Authors:  Christina D Pham; Catherine Flores; Changlin Yang; Elaine M Pinheiro; Jennifer H Yearley; Elias J Sayour; Yanxin Pei; Colin Moore; Roger E McLendon; Jianping Huang; John H Sampson; Robert Wechsler-Reya; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2015-09-24       Impact factor: 12.531

5.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Authors:  Zeng-Jie Yang; Tammy Ellis; Shirley L Markant; Tracy-Ann Read; Jessica D Kessler; Melissa Bourboulas; Ulrich Schüller; Robert Machold; Gord Fishell; David H Rowitch; Brandon J Wainwright; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

Review 8.  The clinical implications of medulloblastoma subgroups.

Authors:  Paul A Northcott; Andrey Korshunov; Stefan M Pfister; Michael D Taylor
Journal:  Nat Rev Neurol       Date:  2012-05-08       Impact factor: 42.937

9.  Novel mutations target distinct subgroups of medulloblastoma.

Authors:  Giles Robinson; Matthew Parker; Tanya A Kranenburg; Charles Lu; Xiang Chen; Li Ding; Timothy N Phoenix; Erin Hedlund; Lei Wei; Xiaoyan Zhu; Nader Chalhoub; Suzanne J Baker; Robert Huether; Richard Kriwacki; Natasha Curley; Radhika Thiruvenkatam; Jianmin Wang; Gang Wu; Michael Rusch; Xin Hong; Jared Becksfort; Pankaj Gupta; Jing Ma; John Easton; Bhavin Vadodaria; Arzu Onar-Thomas; Tong Lin; Shaoyi Li; Stanley Pounds; Steven Paugh; David Zhao; Daisuke Kawauchi; Martine F Roussel; David Finkelstein; David W Ellison; Ching C Lau; Eric Bouffet; Tim Hassall; Sridharan Gururangan; Richard Cohn; Robert S Fulton; Lucinda L Fulton; David J Dooling; Kerri Ochoa; Amar Gajjar; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang; Richard J Gilbertson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962
  9 in total
  3 in total

Review 1.  The evolution of medulloblastoma therapy to personalized medicine.

Authors:  Soma Sengupta; Daniel Pomeranz Krummel; Scott Pomeroy
Journal:  F1000Res       Date:  2017-04-13

Review 2.  CAR T Cell Therapy for Pediatric Brain Tumors.

Authors:  John D Patterson; Jeffrey C Henson; Rebecca O Breese; Kevin J Bielamowicz; Analiz Rodriguez
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244

Review 3.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.